Barclays Maintains Overweight on Ovintiv, Raises Price Target to $62

Barclays analyst Betty Jiang has maintained an Overweight rating on Ovintiv (NYSE: OVV) and raised the price target from $58 to $62. This adjustment reflects a positive outlook for the company's performance in the market.